Cosmo Pharmaceuticals N.V.
Symbol: COPN.SW
SIX
71.4
CHFDzisiejsza cena rynkowa
1009.1513
Wskaźnik P/E
14.6994
Wskaźnik PEG
1.15B
Kapitalizacja MRK
- 0.01%
Rentowność DIV
Cosmo Pharmaceuticals N.V. (COPN-SW) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 50.3 | 241 | 222.2 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 55.1 | 23.6 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 28.5 | 38.6 | 24.5 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 14.2 | 11.5 | 13.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 9.3 | 53.6 | 39.7 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 102.2 | 306.1 | 275.8 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 28.6 | 30.3 | 30.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 24 | 24 | 24 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 355.6 | 366.8 | 372.7 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 379.6 | 390.8 | 396.7 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 3.3 | -46.9 | 25.4 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 14.7 | 18.6 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 40.3 | 64.5 | 58.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 451.8 | 453.5 | 529.7 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 554 | 759.6 | 805.6 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 8.8 | 10.7 | 11.6 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 171.8 | 0.9 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 2.7 | 3.6 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.9 | 1.8 | 169 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.5 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 14.3 | 12.5 | 3.2 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 97.2 | 100.9 | 271.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 2 | 2.6 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 120.3 | 295.8 | 292.9 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 11.5 | 18.4 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 4.6 | 4.6 | 4.6 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 302.6 | 262.2 | 293.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -22.7 | -11.5 | -18.4 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 142.3 | 190.1 | 207.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 426.8 | 456.9 | 505.3 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 554 | 759.6 | 805.6 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 6.9 | 6.9 | 7.4 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | 433.6 | 463.8 | 512.7 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 3.3 | 8.3 | 49.1 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 1.1 | 173.6 | 169.9 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | -49.2 | -12.2 | -28.6 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 24.5 | 24 | -6.9 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.9 | 7.4 | 6 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -21.4 | 5.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 2.1 | 1.5 | 9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -13.3 | -5.1 | -5.1 | |||||||||||||||||||
cash-flows.row.account-receivables | 0 | -14.2 | 3.3 | -7.9 | |||||||||||||||||||
cash-flows.row.inventory | 0 | 1.6 | -6.1 | 0.4 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 14.2 | -3.3 | 7.9 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -14.9 | 1 | -5.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 6.1 | 6.2 | 4.2 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -7.3 | -8.5 | -8.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 23.3 | -4.1 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -54 | -1 | -20 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 35.9 | 7.7 | 131.6 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 27.1 | 3.3 | -23.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 1.7 | 24.9 | 75.4 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -0.9 | -2.6 | -1.8 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.3 | 0.8 | 5.3 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -24.7 | -19.7 | -11 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -15.6 | -0.8 | 0 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -5.1 | -4.9 | -4.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -46.1 | -27.2 | -11.9 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.5 | 2.4 | -1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -12.7 | 12.6 | 75.5 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 185.8 | 198.6 | 185.9 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 198.6 | 185.9 | 110.4 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 33.2 | 12.6 | 13 | |||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -7.3 | -8.5 | -8.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 25.9 | 4.1 | 4.9 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 96.7 | 102.1 | 65.1 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 39.3 | 18.8 | 15.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 57.4 | 83.3 | 49.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 51.7 | 36 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 45.3 | 55.3 | 38.8 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 84.7 | 74 | 54 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 4.5 | 2.9 | 3.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 9.2 | 9 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -4.6 | -3.6 | -9.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 51.7 | 36 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -4.6 | -3.6 | -9.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 9.2 | 9 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 13.6 | 19.4 | 7.4 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | 12.2 | 28.1 | 33.1 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 7.6 | 24.5 | 24 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 6.3 | 7 | 2.3 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | 1.1 | 17.2 | 21.7 |
Często zadawane pytania
Ile wynosi Cosmo Pharmaceuticals N.V. (COPN.SW) aktywów ogółem?
Cosmo Pharmaceuticals N.V. (COPN.SW) całkowite aktywa to 553980000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to N/A.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.593.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 1.901.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.012.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.126.
Co to jest Cosmo Pharmaceuticals N.V. (COPN.SW) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 1147000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 1079000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 45314000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 0.000.